While AI technologies are rapidly developing in medicine, their implementation in daily care is not yet a reality and we should not be overwhelmed by the challenges we face, but instead use resources to develop AI concepts in pharmacogenomic therapies, to make them safer and more practical, and therefore more beneficial for everyone. Adverse drug reactions place a significant burden on the global healthcare system, yet a significant proportion of adverse drug reactions go unreported, leading to bottlenecks in getting proper treatment. This problem is much more pronounced in lower-middle-income countries (LMICs). Despite significant improvements in adverse reaction reporting, the adverse reaction reporting rate remains high with a well-organized pharmacovigilance program in a country like India. An even greater focus on training healthcare professionals in knowledge-based attitudes and practices is likely to further improve adverse event reporting and lead to safer drug use. Combining pharmacogenomics data with artificial intelligence offers exciting opportunities to identify key clinical execution gaps that link rare variants to patient care.